Table 80GRADE profile - PFMT plus EMG plus active NMES compared with PFMT plus EMG plus placebo NMES in patients with multiple sclerosis - Clinical study characteristics and clinical summary of findings

Quality assessmentSummary of findings
No of patientsEffectQuality
No of studiesDesignLimitationsInconsistencyIndirectnessImprecisionPFMT + EMG + NMES Mean (SD)/Frequency (proportion)PFMT + EMG Mean (SD)/ Frequency (proportion)Relative (95% CI)Absolute
Urogenital Distress Inventory
McClurg 20082Randomised trialVery seriousano serious inconsistencyno serious inconsistencyNo serious imprecisionb--Week 24 Irritative sub-scale In favour of PFMT + EMG + NMES vs PFMT + EMG
Leakage episodes per 24 hr
McClurg 20082Randomised trialVery seriousano serious inconsistencyno serious inconsistencyNo serious imprecisionb--Week 9 In favour of PFMT + EMG + NMES vs PFMT + EMG
Week 24 ns
LOW
Post-void residual urine ml (follow-up 9 weeks; Better indicated by lower values)
McClurg 20082randomised trialSeriouscno serious inconsistencyno serious indirectnessSeriousd38 (18)56 (55)MD −18.00 (−36.65 to 0.65)MD 18.00 lower (36.65 lower to 0.65 higher)LOW
Post-void residual urine ml (follow-up 24 weeks; Better indicated by lower values)
McClurg 20082randomised trialSeriouscno serious inconsistencyno serious indirectnessSeriousd38 (23)49 (32)MD −11.00 (−23.7 to 1.7)MD 11.00 lower (23.7 lower to 1.7 higher)LOW
Withdrawals (follow-up 9 weeks)
McClurg 20082randomised trialSeriouscno serious inconsistencyno serious indirectnessno serious imprecision1/37 (2.7%)1/37 (2.7%)RR 1.00 (0.06 to 15.4)0 fewer per 1000 (from 25 fewer to 389 more)MODERATE
a

No details of randomisation, unclear allocation concealment, double blind, ITT analysis, incomplete outcome reporting

b

Imprecision could not be assessed due to incomplete outcome reporting

c

No details of randomisation, unclear allocation concealment, double blind, ITT analysis

d

95%CI crosses the minimally important difference (MID) for either benefit or harm

From: 9, Treatment for stress incontinence

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.